Cline Scientific (CLINE-B.ST) Stock Analysis & AI Equity Report
Cline Scientific (CLINE-B.ST) overview
Cline Scientific (CLINE-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Cline Scientific reported revenue of SEK 4.2m and operating profit of SEK -3.1m; the year-end share price was 0.26 SEK and market capitalisation was SEK 7.8m. Cline Scientific is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cline Scientific's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Cline Scientific
Cline Scientific AB develops cancer diagnostics and regenerative medicine products based on patented surface nanotechnology. The company’s offerings include nano-gradient surfaces and related tools for cell research, along with projects aimed at stem cell therapy for joint repair and cancer diagnostics to predict metastasis. It serves life science and biomedical research applications.
Generate the Cline Scientific report
Cline Scientific is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cline Scientific and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.